June 26, 2022

Medical Trend

Medical News and Medical Resources

First U.S. Revlimid Generic Drug Released: The market still tens billions dollars?

First U.S. Revlimid Generic Drug Released: The market still tens billions dollars?



 

First U.S. Revlimid Generic Drug Released: The market still tens billions dollars?

Teva is now the first drug-maker to launch a generic version of Bristol-Myers Squibb’s Revlimid in the U.S. market.

 

First U.S. Revlimid Generic Drug Released: The market still tens billions dollars?

 

In addition, a number of other companies will also launch generics of Revlimid in the United States this year, and the market is expected to follow up with manufacturers of similar generics soon, including Natco, Sun, Zydus Cadila, Cipla and Dr. Reddy.

Just last month, Sandoz and Stada Arzneimittel revealed that a generic version of Revlimid would also be launched in Europe.

 

It is reported that this time, Teva will launch a one-time generic version of Revlimid in 5 mg, 10 mg, 15 mg and 25 mg doses.

 

Revlimid is a blockbuster immunomodulator obtained after Bristol-Myers Squibb acquired Celgene. The active ingredient of the drug, lenalidomide, is a new-generation derivative of thalidomide with immunomodulatory, anti-angiogenic and anti-tumor properties.

Approved for multiple indications, including multiple myeloma (MM), myelodysplastic syndrome (MDS), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL) .

 

Bristol-Myers Squibb’s Revlimid is on track for $12.8 billion in 2021, but now the company has to face stiff competition from generics.

Previously, in response to these patent challenges, Bristol-Myers Squibb had reached limited generic drug release agreements with a number of companies, which is expected to slow down the price of Revlimid after the generic drug is launched. [Related reading: Top 10 global sales of anticancer drugs in 2021 ]

 

Looking ahead to 2022, Bristol-Myers Squibb expects Revlimid’s sales to reach $9.5 billion to $10 billion this year, with sales falling by $2 billion to $2.5 billion annually thereafter. To that end, the company tried to assuage investor concerns in January, saying it had enough money to absorb Revlimid’s lost revenue.

 

Chief executive Giovanni Caforio has said that its blood thinner Eliquis and immuno-oncology treatments Opdivo and Yervoy will generate additional performance growth of $8 billion to $10 billion a year.

In addition, the company’s recent and upcoming assets will add $10 billion to $13 billion in annual sales, including anemia drug Reblozyl, CAR-T therapy Breyanzi and psoriasis candidate deucravicitinib.

 

 

Reference:

Bristol Myers Squibb’s Revlimid finally faces competition in the U.S. with Teva’s generic launch

First U.S. Revlimid Generic Drug Released: The market still tens billions dollars?

(source:internet, reference only)


Disclaimer of medicaltrend.org